|Bid||168.37 x 900|
|Ask||168.51 x 800|
|Day's Range||166.09 - 169.85|
|52 Week Range||85.00 - 191.63|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||193.73|
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievement of low disease activity and remission, and inhibition of structural damage for different sub-populations of patients living with RA.
Gilead (GILD) beats on Q2 earnings and sales on solid performance of the HIV franchise. The company also raises its sales guidance for the year.
Investors are expected to focus on the HIV franchise's performance and other pipeline updates, when Gilead (GILD) reports second-quarter 2019 results.
Biotech stocks have to be the ultimate risk and reward equities. No other sector comes close to the return potential of the sector. Just take a look at the gains for the SPDR S&P Biotech ETF (NYSE:XBI). The ETF and sector benchmark has managed to post average annual returns of nearly 19% over the last decade. That's pretty insane and underscores the kind of potential that biotech stocks can have.But they also come with a ton of risk to get that return. They don't call them lotto tickets for anything. Many biotech stocks are just one bad trial away from crashing, burning and causing plenty of heartache for their shareholders.However, there are ways to hedge your bets.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAside from going into a broad ETF like the XBI, the key is making sure that investors focus on developmental pipelines, partnership and plenty of cash on their balance sheets. Having a drug actually in the marketing stages doesn't hurt either. It's here that investors can find success in the sector. * 10 Stocks to Buy From This Superstar Fund With that in mind, here are five biotech stocks that have plenty of potential. Galapagos NV (GLPG)Source: Shutterstock A good way to spot top clinical-stage and early-entry biotech stocks is finding those firms with top-notch partners. And Galapagos NV (NASDAQ:GLPG) couldn't have picked a better partner than biotech royalty Gilead Sciences (NASDAQ:GILD). GILD recently upped its partnership stake in GLPG via a nearly $4 billion payment as well as a $1.1 billion equity stake. All in all, Gilead will now own 22% of Galapagos.There's a good reason why GILD would want to pony up that kind of cash for the biotech firm. It needs to fill potential revenue holes in its aging pipeline and GLPG has the goods.Galapagos has one of the richest and largest development pipelines around. The drug company has multiple late-stage programs as well as 25 different drugs in discovery/early trial stages. This includes its potential blockbuster in Filgotinib. This was the first partnership with Gilead and after impressive phase-3 data for the rheumatoid arthritis drug, the duo expects to submit a marketing application with the FDA at the end of the year. Meanwhile, successful initial idiopathic pulmonary fibrosis data, as well as beginning trials for new cystic fibrosis medicines, could all bare significant fruit for GLPG.That's an impressive amount of "shots on goal" for a clinical-stage biotech stock. The best part is, based on the rich deal, the speculation is that Galapagos wanted to stay independent rather than receive a full buyout from GILD. This means it can make the full use of that pipeline with future royalty and milestone payments. It also means investors in GLPG stock can as well. Blueprint Medicines (BPMC)Source: Shutterstock There are a few mega-trends in the world of biotech stocks. Gene therapy is a major one. Another is the concept of small-molecule drugs. Small-molecule drugs are generally more stable than their biologic counterparts and can more commonly be taken as pills as opposed to injections. Though some injected biologics can be taken outside of a healthcare setting (notably Abbvie's (NYSE:ABBV) Humira), many need to be administered by a doctor, nurse or other medical professional. This makes small-molecule drugs better for accessibility and ongoing treatments.This focus on small-molecule drugs makes Blueprint Medicines (NASDAQ:BPMC) a potential real winner among the biotech stocks.BPMC current roster of developmental drugs focuses on various cancers. And the beauty is that pill-delivery system. It really works. Avapritinib -- which treats systemic macrocytosis (SM) and gastrointestinal stromal tumors (GIST) -- managed to shrink these tumors in 86% of the patients treated. That's big any study. The late trial success allowed Blueprint to a marketing application to the FDA for it. The firm has also seen great success targeting other cancers in several other early trials -- with the small -molecule delivery system leading the way. * 7 Stocks to Sell This Summer Earnings Season These successes allowed BPMC to plot its course of action for next year. That should include two marketed drugs, four in application stages and more than a dozen in trials and preclinical investigation. Given the wins already, there's no reason to think blueprint won't get there. Ligand Pharmaceuticals (LGND)Source: Shutterstock If one partner is good, then having over a hundred is better. And this is the case for Ligand Pharmaceuticals (NASDAQ:LGND). LGND counts big shots like Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE) and generic drug specialist Teva (NASDAQ:TEVA) as some of partners/ licensees. The key is Ligand's business model.Ligand doesn't actually develop drugs itself. What it does is provide development platforms that help other biotech stocks and pharmaceutical companies create drugs more effectively. That huge difference has allowed Ligand to quietly become one of the sector's secret stars. Ligand gets upfront payments, development milestones and backend payments on sales after the drugs hit the marketing stages. So far, 10 drugs are now being sold using Ligand's tech. But more are in the late stages of trials.Perhaps the best part is much of the development risk is pushed on the firms using LGND's tech. Ligand gets paid something either way.As a result, LGND is one of the few biotech stocks out there that is actually profitable. Moreover, the steady stream of royalties has allowed the firm to build up a massive war chest of more than $1.4 billion in cash on its balance sheet. While it's too early to talk about dividend potential, LGND could be on its way to initiating a payout in the future as more drugs hit pharmacy shelves using its technology.And yet, shares of LGND could be a massive bargain. After some hype has left the stock, investors can score shares about 505 below peaks hit last summer. Vertex Pharmaceuticals (VRTX)Source: Shutterstock Dominating a disease can mean some big-time revenues for biotech stocks. When it comes to cystic fibrosis, Vertex Pharmaceuticals (NASDAQ:VRTX) is pretty much the only game in town. It's three FDA-approved drugs -- Kalydeco, Orkambi, and Symdeko -- have a monopoly on the disease.]This massive foothold on cystic fibrosis treatments have made VRTX a cash cow for investors. Last year, Vertex managed to sell more than $3 billion worth of medicines to treat the disease. However, this year is looking to eclipse that rate. Already for the first quarter of 2019, VRTX managed to pull in nearly $900 million in revenues alone. That puts it on track reap more than $5 billion in annual sales by 2024. Those robust sales have also helped balloon its cash balance to more than $3.5 billion at the end of the quarter.And the future is robust for Vertex as well.The firm is working on a proved combination therapy of its three drugs to help boosts further, while Symdeko recently received approval from the FDA to be used in children. The best news for VRTX could be a recent foray into gene editing that could treat cystic fibrosis completely. Partnering with CRISPR Therapeutics (NASDAQ:CRSP), Vertex recently started the first human trial using a CRISPR-based product. That drug -- CTX001 -- also received FDA fast track status and could be a huge revenue booster if approved. * 7 Great Sector ETFs to Buy for the Short or Long Term With its strong dominance, hefty cash flows and continued sales increases, VRTX has quickly become one of biotech's brightest stars. BioMarin Pharmaceuticals (BRMN)Source: Shutterstock Thanks to continued advances in science and technology, we're able to tackle more rare and orphan diseases. And thanks to their generally small patient population sizes and difficulty of treatment, drugs targeting this niche of the market often come with sky-high prices. For biotech stocks like BioMarin Pharmaceuticals (NASDAQ:BMRN) this is a revenue win.BRMN has made a name for itself as by only targeting rare diseases and has the most success in this area. The firm currently has seven drugs on the market targeting illnesses such as phenylketonuria and Batten disease. BioMarin has continued to see rising sales and prescriptions for these medications. For example, during the last quarter, the trio of Vimizim, Kuvan, and Naglazyme managed to generate year-over-year revenue growth of 7%, 8%, and 16%, respectively. All in all, total revenues for BRMN topped more than $400 million for the first quarter alone.And those revenues could keep soaring into the future.For one thing, rare disease medications often come with longer exclusivity rights. This gives BMRN a very long runway to ward off generic competition. Secondly, rare disease medications generally have no trouble getting covered by health insurers. This allows patients to actually get their hands on the high-priced meds in the first place.Adding in BioMarin's beefy pipeline and you have a recipe for success. Analysts expect the firm to finally start turning a profit by 2020 -- especially if its new hemophilia drug turns out to be a blockbuster.Disclosure: At the time of writing, Aaron Levitt was Long CRSP and the iShares NASDAQ Biotechnology ETF (IBB) -- which owns all the stocks on this list. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy From This Superstar Fund * 7 Stocks to Buy This Summer Earnings Season * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk The post 5 Biotech Stocks to Buy for a Strong Growth Prognosis appeared first on InvestorPlace.
Mechelen, Belgium; 18 July 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Van Herk Investments.
Moody's Investors Service commented that Gilead Sciences, Inc.'s new research and development collaboration with Galapagos NV is credit positive for Gilead. There are no changes to Gilead's A3 existing senior unsecured rating or stable rating outlook. For additional information please refer to Moody's issuer comment on Gilead available on www.moodys.com.
There will be a bundle of earnings reports that start to roll out this week. On Monday morning we had a few, but it's about to get busy in the second half of July. Given how much is set to come out over the next few weeks, it was a relatively quiet day on Wall Street Monday. We saw an 0.17% gain in the Nasdaq today, followed by slight gains for the S&P 500 and Dow Jones.Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat said, there's a lot individual news to dig through. Bitcoin, Libra and CryptoThe bitcoin market has been wildly volatile lately, hasn't it? Bitcoin prices ran from $5,500 at the start of May to more than $8,700 by June 1st. Just a few weeks later it was north of $13,000. It topped out around $13,600, before it promptly fell to just under $10,000. Crypto bulls said it was an opportunity. Bears argued it was a blowoff top and it was coming back down. Another run to $13,000 earlier this month was again met with sellers as bitcoin prices dropped back down to $10,000. * 7 Dependable Dividend Stocks to Buy I'll stop the onslaught of price history, but it's sort of necessary for an asset like bitcoin. Put simply, this thing is volatile. Perhaps we're entering a range-bound trade, between $10,000 and $13,000. At the very least, traders now have a few lines in the sand, where a move above resistance or below support could spell a further move in that direction. The advances in bitcoin have helped give a boost to Facebook (NASDAQ:FB) stock, even as it's drawn the ire of regulators for its Libra cryptocurrency. Congress has asked Facebook to hold off on Libra until it knows more. It's drawn comments from the president, while U.S. Treasury Secretary Steven Mnuchin said the Treasury has serious concerns over Libra.For its part, Facebook -- which will reportedly settle with the FTC for $5 billion -- said it will wait until it has regulatory support before launching. Heard at the Nasdaq TodayShares of Gilead Sciences (NASDAQ:GILD) were on the move Monday, rising 2.7% and closing at $68.07. It will invest $5.1 billion in Galapagos (NASDAQ:GLPG), increasing its stake in the company from 12.2% to 22%. Galapagos will now see if shareholders approve an eventual stake increase to 29.9%. Given today's action, it's hard to see shareholders saying no, with GLPG stock rising more than 17% to new highs. Further, Gilead Sciences stock was upgraded to outperform at Wells Fargo. The analysts assigned an $88 price target, implying about 30% upside from current levels and signaling new 52-week highs should GILD stock get there. OK, so what's going on with Broadcom (NASDAQ:AVGO) and Symantec (NASDAQ:SYMC)? Broadcom was reportedly in talks to acquire SYMC. However, on Monday, shares of Symantec abruptly tumbled lower, falling over 10% on news that AVGO is no longer in talks to buy the company. However, the stock recovered off its initial lows -- and actually closed at session highs -- while AVGO stock rallied almost 3% on the news, before ending higher by just 1%. New reports say that Broadcom isn't walking away from the deal just yet. So what gives? This is just typical M&A drama. I don't know if Broadcom will pull the trigger for SYMC. Maybe the latter wanted even more money. Perhaps the terms weren't right. Either way, the market seems happy for AVGO to walk away, if that should be a sign of anything. Broadcom stock has been under pressure since the buyout news surfaced and rallied when it looked like the deal was off. Movers in the Nasdaq Today Click to EnlargeAlphabet's (NASDAQ:GOOGL, NASDAQ:GOOG) Google, as well as several social media sites have fallen under criticism that they display a political bias. Google's vice president of government affairs Karan Bhatia wrote an op-ed stating that the company does not have a bias and stated he will tell U.S. Senators that is the case as well. Social media is playing an enormous role in the distribution of political news, both real and fake. It's created a frenzy of both misinformation and information overload, drawing criticism from both political parties. No matter which side of the aisle readers stand on, they should be reading factually correct information, although tech companies haven't seemed to find a very good way to govern it thus far. Tesla (NASDAQ:TSLA) stock is hitting its highest levels since May, rising 3.4% on Monday on above-average volume. The stock is now running into prior support though, which acted as resistance a few months ago. The stock has to reclaim this area to really get the bullish train moving. Amazon's (NASDAQ:AMZN) much-awaited Prime Day is finally here, with sales going strong on Monday and Tuesday. The e-commerce retailer will pull in billions in revenue from the event and is drawing in competition from seemingly every online retailer (seriously, have you checked your inbox lately?) * 5 EV Stocks to Buy for Big Gains Over the Next Decade Target (NYSE:TGT), Costco (NASDAQ:COST), Home Depot (NYSE:HD) -- three strong retailers by the way -- have been hitting it hard, as has Walmart (NYSE:WMT), Best Buy (NYSE:BBY) and others. With a strong labor market, I would expect Amazon's Prime Day numbers to be solid this year. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long AVGO, GOOGL and AMZN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dependable Dividend Stocks to Buy * 10 Stocks Driving the Market to All-Time Highs (And Why) * 7 Short Squeeze Stocks With Big Upside Potential The post Nasdaq Today: Bitcoin & Libra; Whatas Broadcom Doing? appeared first on InvestorPlace.
A Galapagos deal with Gilead has GLPG stock heading higher on Monday.Source: Shutterstock As part of a larger deal with Galapagos (NASDAQ:GLPG), Gilead (NASDAQ:GILD) will be purchasing a stake in the company. This will have it acquiring new shares of GLPG stock for €140.59 each. This represents a 20% premium over the stock's 30-day, volume-weighted average price.The Galapagos deal will have Gilead increasing its stake in the company by a fair amount. This will have its ownership of GLPG stock increasing from 12.3% to 22%. Galapagos is also seeking approval from shareholders to allow for two warrants to Gilead. This will let it increase its stake in the company to 29.9%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis Galapagos deal doesn't just stop with an investment from Gilead. It will also have the two companies working together. This includes a $3.95 billion payment from Gilead that will allow the company to work more on its research and development programs.The Galapagos deal will make it so that Gilead gains exclusive access to the results of research. That will include "exclusive product license and option rights to develop and commercialize all current and future programs in all countries outside Europe." * 7 Dependable Dividend Stocks to Buy There's also the option for additional payments if things go well for Galapagos. For example, Gilead is willing to pay an additional $325 million to the company if GLPG1690 gets approval in the U.S. It will also have the ability to pay a $250 million fee to license the compound for use in the U.S.GLPG stock was up 17% and GILD was up 2% as of Monday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dependable Dividend Stocks to Buy * 10 Stocks Driving the Market to All-Time Highs (And Why) * 7 Short Squeeze Stocks With Big Upside Potential As of this writing, William White did not hold a position in any of the aforementioned securities.The post Galapagos Deal: GLPG Stock Rockets Higher on Gilead Stake appeared first on InvestorPlace.
(Bloomberg Opinion) -- Gilead Sciences Inc.’s new CEO Daniel O'Day is trying to replicate the successful playbook of his former employer Roche Holding AG, the Swiss pharma giant he worked at for more than 30 years. On Sunday, Gilead announced that it would invest $5.1 billion to deepen an existing relationship with Belgian biotechnology firm Galapagos NV. O'Day isn't just committing to Galapagos – he’s committing to the idea of research partnerships that stop short of outright M&A. The deal includes a 10-year standstill agreement that restricts Gilead's ability to acquire the company. O'Day thinks that leaving Galapagos independent will keep it innovative, a bet that paid off for Roche and its productive long-term partnerships with Genentech and Chugai Pharmaceutical Co. That nebulous benefit will have to come through in a big way to justify the price and structure of this deal. Gilead is paying $3.4 billion upfront to gain rights to six drugs in clinical trials and access to a suite of earlier-stage programs. It is also making a $1.1 billion equity investment in Galapagos.The total outlay is a scant $2 billion less than the market cap of Galapagos before the deal was announced, and is above what the company was worth as recently as March. On top of that, Gilead already owned 12 percent of Galapagos and rights to potential blockbuster arthritis drug filgotinib from a $725 million deal completed in 2015. O'Day also isn't done paying up. He will have to shell out more cash to opt in to future programs and for development costs. Gilead will also pay a significant sales royalty if any drugs are approved. And Galapagos will retain European rights for most of its medicines. The potential return of this deal is lower than an outright acquisition, and Gilead didn't seem to get much of a discount. It’s giving up a lot to limit its risk and test the abstract notion that partnerships are superior. The company's late-stage pipeline is sparse, and it is too reliant on its HIV franchise. It’s not in a position to leave upside on the table. There’s a chance that the deal could work out. Gilead’s only has to pay $150 million to gain exposure to programs that are currently in early stages; that could wind up being a relative steal at some point in the next decade. Investors may feel a twinge with every opt-in and royalty check, however. Gilead had chances during the past few years to acquire Galapagos at a lower price than what it’s paying for the partnership now. That feels like a missed opportunity, and may seem even more so if its pipeline and R&D platform turn out to be as strong as O’Day seems to think they are.To contact the author of this story: Max Nisen at email@example.comTo contact the editor responsible for this story: Beth Williams at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
Gilead said it will make a $3.95-billion upfront payment and $1.1-billion equity investment in the Belgian pharmaceutical company, according to a Sunday press release. Galapagos intends to use the proceeds to expand its research and development programs. As part of a 10-year global research and development collaboration; Gilead will have access to a portfolio of compounds, including six molecules in clinical trials, more than 20 preclinical programs and a drug discovery platform. Galapagos shares were trading higher by 16.34% at $169.56 at the time of publication.
Daniel O'Day watched as Roche, where he was a top executive, took a piece of Genentech, then ultimately bought the South San Francisco company. Now as the chairman and CEO of Foster City-based Gilead Sciences, a deal with a Belgian biotech feels similar.
Shares of the European drugmaker Galapagos are soaring after (GILD) said over the weekend that it would spend $5 billion on a collaboration agreement with the firm. Instead of embarking on a pharmaceutical megamerger, of the sort Barron’s has argued against, Daniel O’Day, Gilead’s new CEO, signed a 10-year deal with longtime collaborator Galapagos (ticker: GLPG) to boost his company’s pipeline of potential treatments. “I firmly believe [in] the concept that we’ve come up with, the concept of enabling Galapagos with a significant capital infusion for them to further invest in that research and at the same time keeping their independence as a premier European biotech company that allows them to recruit the very best talent, make their own decision and progress programs according to their judgment,” O’Day said on a conference call about the deal.